PTLA - Glancy Prongay & Murray LLP Announces Investigation on Behalf of Portola Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Portola Pharmaceuticals, Inc. (“Portola” or the “Company”) (NASDAQ: PTLA) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On January 9, 2020, Portola announced that it only expected $28 million revenue for Andexxa in fourth quarter 2019, well below expectations of revenue between $39 million and $41 million.

On this news, the Company’s share price fell as much as $10.55, or nearly 43%, during intraday trading on January 10, 2020, thereby injuring investors.

If you purchased Portola securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles H. Linehan, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005509/en/